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Abstract
Objective: Systematic reviews highlight a broad range of cancer-related post-traumatic stress disorder
(CR-PTSD) prevalence estimates in cancer survivors. This meta-analysis was conducted to provide a
prevalence estimate of signiﬁcant CR-PTSD symptoms and full diagnoses to facilitate the psychological
aftercare of cancer survivors.
Methods: A systematic literature search was conducted for studies using samples of cancer survivors
by using validated clinical interviews and questionnaires to assess the prevalence of CR-PTSD (k= 25,
n= 4189). Prevalence estimates were calculated for each assessment method using random-effects
meta-analysis. Mixed-effects meta-regression and categorical analyses were used to investigate
study-level moderator effects.
Results: Studies using the PTSD Checklist—Civilian Version yielded lower event rates using cut-off
[7.3%, 95% conﬁdence intervals (CI) = 4.5–11.7, k=10] than symptom cluster (11.2%, 95% CI=8.7–
14.4, k=9). Studies using the Structured Clinical Interview for Diagnostic and Statistical Manual, Fourth
Edition (SCID), yielded low rates for lifetime (15.3%, 95% CI=9.1–25, k=5) and current CR-PTSD
(5.1%, 95%CI=2.8–8.9, k=9). Between-study heterogeneity was substantial (I2 = 54–87%). Studies with
advanced-stage samples yielded signiﬁcantly higher rates with PTSDChecklist—Civilian Version cluster
scoring (p=0.05), andwhen assessing current CR-PTSD on the SCID (p=0.05). The effect ofmean age on
current PTSD prevalence met signiﬁcance on the SCID (p=0.05). SCID lifetime prevalence rates
decreased with time post-treatment (R2 = 0.56, p< 0.05).
Discussion: The cancer experience is sufﬁciently traumatic to induce PTSD in a minority of cancer
survivors. Post-hoc analyses suggest that those who are younger, are diagnosed with more advanced
disease and recently completed treatment may be at greater risk of PTSD. More research is needed
to investigate vulnerability factors for PTSD in cancer survivors.
© 2014 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.
Introduction
Systematic reviews show that long-term cancer survivor-
ship is accompanied by co-morbid depression, anxiety
and symptoms of post-traumatic stress disorder (PTSD)
[1–4]. The PTSD Field Trials for the Diagnostic and
Statistical Manual, Fourth Edition (DSM-IV) [5], revealed
that 22% of cancer survivors present with lifetime cancer-
related PTSD (CR-PTSD) [6], endorsing cancer diagnosis
and treatment as a traumatic stressor. This inspired
research into the prevalence and presentation of CR-PTSD
in cancer populations [7].
According to DSM-IV [5], PTSD can develop when an
individual experiences a traumatic event that threatens their
psychological and/or physical integrity (criterion A1), and
they react with helplessness or horror (criterion A2). They
typically re-experience the memories, sensations and
emotions from the event through sensory ﬂashbacks and
nightmares (criterion B), avoid trauma reminders and can
be emotionally numb (criterion C), anxious, irritable and
hyper-vigilant (criterion D). These symptoms are patholog-
ical when their duration is more than 1 month post-trauma
(criterion E) and causes socio-occupational impairments
(criterion F). Using the DSM-IV criteria, studies to date iden-
tiﬁed lifetime rates from 5% [7] to 35% [8]. However, the re-
cent publication of the DSM-5 [9] challenges this position.
The new trauma criterion states ‘…a life-threatening…or
debilitating medical condition is not necessarily considered
a traumatic event. Medical incidents that qualify as traumatic
events involve sudden, catastrophic events [e.g., waking
during surgery, anaphylactic shock]’ (p. 274).
A recent article by Kangas [10] discussed how the new
PTSD diagnostic criteria would affect the psychological
aftercare of individuals who have completed cancer treat-
ment—a population we will deﬁne as cancer survivors.
Consequently, a PTSD diagnosis is less likely to be given
to those who present with PTSD symptoms, in favour of
DSM-5’s adjustment disorder (AD). AD is a diagnosis
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given to individuals who either (a) present with
subsyndromal PTSD or (b) experience the complete PTSD
syndrome in response to an event that is not considered
traumatic [9]. Kangas [10] argued that relatively few
DSM-IV studies investigated the rates of AD and PTSD
in cancer samples and, thus, could not determine if PTSD
was the primary disorder. This casts doubt on the appropri-
ateness of PTSD as a diagnosis for cancer survivors but
emphasises the need to correctly diagnose a cancer survivor
who presents with trauma/stress-related symptoms.
It does not, however, address the needs of oncology
specialists to know the proportion of patients who would
likely develop PTSD or AD, or of the factors contributing
to their presentation. In systematic reviews to date [1–4],
efforts to achieve a prevalence estimate have been im-
peded owing to the substantial variability in rates, which
is often attributed to extreme between-study heterogeneity
in assessment methods (e.g. questionnaire versus clinical
interview), assessment points (post-diagnosis or post-
treatment) and sample characteristics such as severity of
disease, or mean age [11].
Firstly, many studies use different methods of estimating
(or diagnosing) PTSD. The most obvious example of this is
the use of clinical interviews, such as the ‘gold standard’
Clinician-Administered PTSD Scale (CAPS) [12], or the
Structured Clinical Interview for DSM-IV (SCID) [13],
which yields a full DSM-IV PTSD diagnosis (criteria A–
F), versus screening questionnaires such as the PTSD
Checklist—Civilian Version (PCL-C) [14], which assesses
symptom severity (criteria B–D). Although the PCL-C has
been criticised for not establishing the fulﬁlment of PTSD
criterion A [15], it has been administered to cancer patients
and survivors in the context of experiencing cancer as a
traumatic event (criterion A1). It can also assess PTSD
symptoms over the past month (criterion E) and has been
used frequently to assess PTSD symptom severity and pro-
vide a tentative PTSD diagnosis. Andrykowski et al. [16]
validated the PCL-C against the SCID [13], and its factor
structure has been corroborated in cancer survivors
[17,18]. Therefore, the PCL-C is arguably a useful question-
naire to assess PTSD symptom severity and has sufﬁcient
sensitivity and speciﬁcity to screen for a probable PTSD di-
agnosis. Nevertheless, like other screening questionnaires,
the PCL-C has been known to inﬂate PTSD prevalence rates
owing to (a) the endorsement of PCL-C items that are con-
founded by disease symptoms [19]; (b) the inability to as-
sess functional impairment (criterion F); and (c) whether
cut-off scores are used or using a symptom cluster method
by imitating the DSM-IV-TR PTSD diagnostic criteria
[20]. The proximity of psychological assessment (by either
questionnaire or structured interview) to the end of diagno-
sis or treatment may also contribute to prevalence. Evidence
for this is equivocal; some studies have shown that PTSD
persists even 20 years after the cancer experience [21],
whereas others reveal no relationship between PTSD
symptom severity and time since diagnosis [6,22–25] or
time since treatment [26,27].
Secondly, heterogeneity may emerge from sample charac-
teristics. Younger age at cancer diagnosis is associated with
more severe PTSD symptoms [15,17,23,24,26,28–31],
although some studies have not found a signiﬁcant associa-
tion [21,25,27]. Recent meta-analyses have demonstrated
that younger samples of medical trauma survivors are
associated with higher PTSD prevalence rates [32]. The
disease characteristics of each study sample may also
contribute. Gurevich et al. [1] argued that many studies that
report no relationship between disease severity and CR-
PTSD prevalence rates are actually skewed towards early
disease stages [6,15,26,28–30]. However, samples that are
more evenly distributed report signiﬁcant effects of disease
staging on prevalence rates [8,27,33,34]. In order to counter
this heterogeneity, it has been argued that future studies of
PTSD in cancer populations would beneﬁt from larger,
broader samples [35]. Therefore, a meta-analysis of studies
reporting CR-PTSD prevalence statistics was conducted in
order to ﬁnd an empirical estimate of the proportion of adult
cancer survivors who will present with (a) clinically
signiﬁcant PTSD symptoms or (b) a full diagnosis of PTSD
under DSM-IV criteria. Our aims were as follows:
1. To establish a mean PTSD prevalence estimate for
CR-PTSD in adult cancer survivors, with regard to
the use of diagnostic interview methods and screening
questionnaires. This will provide an estimate of the
presentation of full-PTSD, and caseness-level PTSD
symptoms indicating the need for a full assessment,
respectively.
2. To establish what percentage of variance in preva-
lence estimates can be explained by between-study
heterogeneity, with a focus on disease-stage sample
characteristics, mean sample age and time since
diagnosis or treatment. This will provide evidence
for patient variables that may be risk factors for the
development of PTSD.
Method
Search strategy
Seven online databases (MEDLINE, PsycARTICLES,
PsycINFO, CINAHL Complete, CINAHL Plus, Aca-
demic Search and E-Journals) were searched systemati-
cally. Studies published from 1994 (the publication of
the DSM-IV) to 11 June 2013 were included. The search
terms (cancer) AND (PTSD) AND (prevalence) were used
for every database. It was decided to adopt such broad
terms to capture as many studies as possible that are
focused on the number of CR-PTSD cases in their sample.
Dissertations were included in the search, but case studies,
and studies that were unavailable in English, were
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excluded. Systematic reviews from 1999 onwards
concerning CR-PTSD in survivors of adult cancers were
examined, and any relevant references from these reviews
that were not returned in online databases were abstracted.
The following inclusion/exclusion criteria were compiled
by the primary and secondary authors following an
investigation of issues identiﬁed in the aforementioned
systematic reviews and were agreed on by consensus of
all the authors.
Inclusion and exclusion criteria
Articles were included if they met these criteria: (1) they
were conducted with, and specify, a sample of cancer
patients (those who are in treatment) or survivors (those
who have completed treatment). Note that the search
strategy does not specify any particular cancer owing to
the systematic reviews arguing the scarcity of evidence
for the effect of disease variables on CR-PTSD prevalence
rates; (2) they provide PTSD prevalence estimates (i.e. the
number of people in the sample who meet caseness); (3)
the prevalence statistics are in reference to cancer diagno-
sis and treatment as the traumatic stressor (CR-PTSD); (4)
they provide summary statistics on (a) disease stages in
the sample, (b) gender, (c) mean age of sample and (d)
mean time post-diagnosis or post-treatment; (5) they use
both or either of the structured clinical interviews such
as the CAPS [12], SCID [13], Watson’s PTSD Inventory
[36] or a validated screening questionnaire that is based
on DSM-IV PTSD criteria such as the PCL-C [14], or
PTSD Reaction Index [37]; and (6) use cross-sectional,
or longitudinal/prospective, methods. Articles were
excluded if they (1) used the Impact of Events Scale
as a standalone measure of probable PTSD [38]; (2)
speciﬁcally used samples of adult survivors of child-
hood cancers; or (3) used the same sample as another
included study.
Study selection
After the removal of duplicate entries, the full texts of the
remaining records were read by the primary author.
Studies that clearly met exclusion criteria (e.g. did not
use cancer samples or used the Impact of Events Scale
as a standalone PTSD measure) were excluded by the
primary author. All authors read the remaining full-text
articles and selected from the remaining studies those that
they believed met inclusion criteria, and discrepancy
between authors was resolved by full consensus.
Data abstraction
All prevalence ﬁgures, sample characteristics and study
methods were abstracted onto a spreadsheet for review by
the primary author and re-checked four times to ensure ac-
curate data abstraction, and a random sample of the included
studies was independently checked by a clinical psychology
postgraduate (Table 1). There was full agreement. Although
most of the data are easily abstracted in their presented form
(e.g. mean age, gender, event rates and assessment method),
some statistics were calculated manually. For example, in
order to assess the moderating effect of disease-stage
distribution on CR-PTSD prevalence rates, a summary
statistic on the skew of the sample distribution had to be
used. Given that many studies are skewed towards low
disease stages, the mode (0, 1, 2, 3 or 4) was used to depict
the disease stage that was most frequent in each sample.
There were k= 4 studies that were bimodal; in these cases,
all bimodal distributions were characterised by I–II, II–III
or III–IV, so given the nature of cancer-stage progression,
the mean was used (1.5, 2.5 and 3.5, respectively). In some
cases, the sample size reported in abstracts did not reﬂect
that in the ﬁnal analysis, so our abstracted ns reﬂected only
those participants who completed the study. Finally, some
authors reported time since diagnosis or treatment using dif-
ferent units (days/weeks rather than months). All studies
were converted to the number of months. In all cases where
it was reported in days or weeks, a month was treated as
30 days, and weeks were multiplied by seven and then
divided by 30 to obtain the number of months.
A priori statistical methods and analysis
All statistical analyses and graphical presentations were
conducted using Comprehensive Meta-analysis (CMA)
[39]. Prevalence statistics were depicted using the event
rate. Ninety-ﬁve percent conﬁdence intervals (CIs) were
calculated within the CMA software using the sample size
(n) and standard error. When prospective studies were
included in the analysis, the time 1 (T1) measurements
(being temporally associated with study-level moderators
such as time since diagnosis and/or treatment) were used
to calculate the event rates. In cases where the T1
measurements were not post-treatment, the T2 prevalence
estimates (and the mean time post-treatment) were used.
This was the case for one study only [34]. All meta-
analyses were conducted under a random-effects model
owing to the substantial methodological heterogeneity
identiﬁed in systematic reviews. Mixed-effects meta-
regression was used to examine the association between
continuous variables such as time since diagnosis or
treatment end and mean age of sample, on CR-PTSD
prevalence rates. Categorical analyses were conducted
on studies where samples were characterised by either
early (I–II) or advanced (III–IV) disease stages, and also
on population studies (USA/Canada, UK/Europe and
eastern countries). Finally, publication bias was assessed
using funnel plots. These plots depict the spread of
prevalence rates according to (a) interviews and screeners,
(b) symptom cluster and cut-off scoring for screening
questionnaires and (c) current versus lifetime CR-PTSD for
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clinical interviews. In order to calculate the variance contri-
bution of statistically signiﬁcant study-level moderators on
PTSD event rates, we calculated the R2 statistic using the
following formula: R2 ¼ 1  T2unexplained=T2total
 h i
.
Results
Literature search and study characteristics
We identiﬁed 257 articles. After duplicates were removed,
109 articles remained. A combined total of 138 studies
were recovered from online databases and systematic
reviews. Figure 1 depicts the PRISMA search strategy
[40]. Table 1 presents the abstracted prevalence data and
study/sampling characteristics for the ﬁnal dataset
(k= 25). The aggregated sample was n= 4189, of which
88% were female, and the study of Mystakidou et al.
[41] was the only study to represent both genders. In terms
of methodology, k = 19 studies were cross-sectional, and
k = 6 were longitudinal/prospective. The majority of
studies were conducted in the USA (k = 18), with one in
Japan, ﬁve in Europe and the UK, and one in Israel.
Although there was a range of cancers included, 21 studies
used exclusively female breast cancer samples, with one
study using ovarian cancer [42], one gynaecological
cancer [34] and two inclusive of breast cancer, but with
the addition of others [6,41]. Owing to the low n for
cancers other than breast, an analysis of the moderating
effects of cancer type could not be conducted. Therefore,
a separate analysis was conducted on breast cancer alone,
as this is the most frequently studied cancer population.
Also, the moderating effects of gender were not analysed
owing to the predominance of women over men in the
ﬁnal dataset.
CR-PTSD prevalence rates
The results of the meta-analysis are available in Table 2.
The table presents prevalence statistics for the whole pool
of cancer studies and for breast cancer alone, grouped by
Figure 1. PRISMA ﬂow chart of systematic review procedure
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assessment strategy, from clinical interview methods
(SCID, CAPS and Watson’s PTSD Inventory) to question-
naires (PCL-C, PTSDDiagnostic Scale (PDS), PTSD Reac-
tion Index and PTSD Scale). Separate statistics are provided
for the PCL-C and SCID given their use in the majority of
studies. See Supporting Information Figures 2–6 for forest
and funnel plots.
All cancer types: Studies that used the PCL-C yielded
lower event rates using the cut-off method (7.3%, 95%
CI = 4.5–11.7, k= 10) compared with the symptom cluster
method (11.2%, 95% CI = 8.7–14.4, k= 9). Studies using
the SCID alone yielded higher lifetime diagnoses
(15.3%, 95% CI = 9.1–24.7, k= 5) than current diagnoses
(5.1%, 95% CI = 2.8–8.9, k= 9). Studies using a clinical
interview method yielded a combined event rate of 6.4%
(95% CI=4.1–9.9, k=12) for current CR-PTSD and
12.6% (95% CI=7.5–20.7, k=7) for lifetime CR-PTSD.
Studies that used a cut-off score screening method used the
PCL-C exclusively. All other screening tools used a symp-
tom cluster method and yielded similar prevalence estimates
to the PCL-C cluster method (13.8%, 95% CI=9.5–19.6,
k=11). No comparison could be performed between
interview methods, or between screening tools, because only
the PCL-C and the SCID were used more than once.
Although the point estimates for each assessment method
are comparable, each is characterised by considerable
between-study heterogeneity across cancer samples
(Table 2; I2 = 54–86%).
Breast cancer: Studies that used the PCL-C yielded
lower event rates using the cut-off method (6.4%, 95%
CI = 4.2–9.7, k= 9) compared with the symptom cluster
method (11.2%, 95% CI = 8.7–14.4, k= 9). These ﬁgures
are similar to those found across cancers, although the
cut-off event rate for breast cancer alone is 1% less.
The rates for the symptom cluster method here are
the same for breast cancer as for all cancers. Studies
using the SCID alone yielded lower but nevertheless
comparable event rates for current CR-PTSD (4.1%, 95%
CI = 2–8.5, k=7). Much higher rates were found for lifetime
CR-PTSD (14.2%, 95% CI= 7.7–24.9, k=4). Studies that
used a clinical interview method yielded a combined
event rate of 5.8% (95% CI = 3.3–10, k = 10) for current
CR-PTSD and 11.5% (95% CI = 6.3–20.1, k = 6) for
lifetime CR-PTSD. Studies using the cut-off scoring
method used the PCL-C exclusively (see aforementioned re-
sults). All other screening tools used a symptom cluster
method and yielded remarkable similar prevalence estimates
to the PCL-C cluster method (12.1%, 95% CI=9.3–15.7,
k=10). Similar between-study heterogeneity was observed
for breast cancer samples (I2 = 54.4–81.5%).
Sources of heterogeneity
Mean sample age, mean time since diagnosis and mean
time since end of treatment were entered into a meta-
regression for their variance contribution to CR-PTSD
prevalence rates. Early or advanced modal disease staging
and population of origin (USA, UK and Europe, Japan
and Israel) were analysed categorically to assess group
differences in prevalence.
Table 2. PTSD event rates (a) across cancers and (b) for breast cancer samples, according to method of assessment
Cancer-related PTSD
measure
k
%
Event
rate
95% CI
p
Heterogeneity Tau2
Lower Upper Q d.f. I2 p Tau2 Tau SE Variance
Breast cancer
By assessment method
Interview Current 10 5.8 3.3 10 <0.01 33.4 9 73.05 <0.01 0.61 0.78 0.42 0.18
Lifetime 6 11.5 6.3 20.1 <0.01 27.01 5 81.5 <0.01 0.53 0.73 0.44 0.19
Questionnaire Cut-off 9 6.4 4.2 9.7 <0.001 17.56 8 54.44 <0.01 0.24 0.49 0.23 0.06
Cluster 10 12.1 9.3 15.7 <0.01 28.14 9 68.02 <0.01 0.14 0.37 0.12 0.01
By speciﬁc tool
SCID Current 7 4.1 2 8.5 <0.001 21.89 6 72.59 <0.001 0.7 0.83 0.61 0.37
Lifetime 4 14.2 7.7 24.9 <0.001 15.55 3 80.71 <0.001 0.4 0.63 0.42 0.17
PCL-C Cut-off 9 6.4 4.2 9.7 <0.001 17.56 8 54.44 <0.03 0.24 0.49 0.23 0.06
Cluster 9 11.2 8.7 14.4 <0.001 18.8 8 57.45 <0.02 0.1 0.31 0.1 0.01
Across cancers
By assessment method
Interview Current 12 6.4 4.1 9.9 <0.01 42.8 11 74.29 <0.01 0.41 0.64 0.34 0.11
Lifetime 7 12.6 7.4 20.7 <0.01 28.73 6 79.2 <0.01 0.49 0.7 0.38 0.15
Questionnaire Cut-off 10 7.3 4.5 11.3 <0.01 31.4 9 71.33 <0.01 0.47 0.68 0.33 0.11
Cluster 11 13.8 9.5 19.6 <0.01 75.89 10 86.82 <0.01 0.41 0.64 0.29 0.08
By speciﬁc tool
SCID Current 9 5.1 2.8 8.9 <0.001 35.46 8 77.43 <0.001 0.53 0.72 0.49 0.24
Lifetime 5 15.3 9.1 24.7 <0.001 16.64 4 75.96 <0.001 0.34 0.59 0.33 0.11
PCL-C Cut-off 10 7.3 4.5 11.7 <0.001 31.4 9 71.33 <0.001 0.47 0.68 0.33 0.11
Cluster 9 11.2 8.7 14.4 <0.001 18.8 8 57.45 <0.001 0.09 0.31 0.01 0.01
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Time post-diagnosis was not signiﬁcant for any analyses.
Time post-treatment was not signiﬁcant when using the
SCID, PCL-C or the questionnaire method but was
signiﬁcant when including other clinical interviews to assess
lifetime CR-PTSD [Qmodel(1) = 3.84, T2unexplained = 0.22 k=3,
p=0.05], with CR-PTSD event rates decreasing when time
since treatment increases, and a variance contribution of
56% (R2 = 0.56, p< 0.05). The contribution of mean sample
age to prevalence was not signiﬁcant for breast cancer
samples, or when using the cut-off and cluster screening
methods and the clinical interview method, or when using
the SCID to assess lifetime CR-PTSD in all cancers.
However, it was signiﬁcant when using the SCID to assess
current CR-PTSD [Qmodel (1) = 0.43, p=0.05].
Disease stage was signiﬁcant when using the SCID to
assess current CR-PTSD [Q(1) = 10.23, p= 0.05]. Studies
characterised by early stages (I–II) yielded markedly
lower prevalence rates (4.2%, 95% CI = 2.1–8.1, k= 8,
n= 737) than those with advanced-stage (III–IV) disease
(11.4%, 95% CI = 9.6–13.5, k= 1, n = 989). This was also
true for the interview method [Q(1) = 6.07, p= 0.01], with
the only difference in effect coming from the additional
interview methods other than the SCID in the early-stage
group (5.7%, 95% CI = 3.4–9.6, k= 11, n= 970). Finally,
the use of the questionnaire method with cluster scoring
also yielded a signiﬁcant difference [Q(1) = 3.71,
p= 0.05] with early stages yielding signiﬁcantly lower
prevalence rates (11.6, 95% CI=8.8–13.5, k=9, n=1894)
than advanced-stage samples (31.3 95% CI = 11.8–61,
k = 2, n = 112). This moderator was not signiﬁcant for
pure breast cancer samples.
Population was not a signiﬁcant moderator when using
the questionnaire method or on the PCL-C, or the SCID,
alone, and in either the full cancer sample or breast cancer
samples. But signiﬁcant differences were found when
using the clinical interview method to diagnose current
CR-PTSD [Q(3) = 9.2, p= 0.03], with Israel having
signiﬁcantly higher rates (18%, 95% CI = 8.8–33.2,
k= 1) than the USA (5.6%, 95% CI = 2.6–11.6, k= 8),
Europe (6%, 95% CI = 2.4–14, k= 3) or Japan (3.9%,
95% CI = 1.8–8.4, k= 1). Population was also signiﬁcant
for lifetime CR-PTSD [Q(2) = 11.28, p = 0.03], with the
USA (15.4%, 95% CI = 8.4–26.7, k= 5) and Japan
(14.8%, 95% CI = 10–21.3, k= 1) having higher rates than
Europe (2.8%, 95% CI = 1.1–7.2, k= 1). Population was
signiﬁcant in exclusively breast cancer samples when
diagnosing lifetime CR-PTSD with the interview method
[Q(2) = 10.83, p< 0.01], with the UK and Europe (2.8%,
95% CI = 1.1–7.2) having a signiﬁcantly lower prevalence
than the USA (14.2%, 95% CI = 6.8–27.5, k= 4) and
Japan (14.8, 95% CI = 10–21.3, k= 1). Similar trends in
breast cancer were found when diagnosing current CR-
PTSD [Q(3) = 11.43, p< 0.01], with Israel yielding higher
rates (18%, 95% CI = 8.8–33.2, k= 1) than Japan (3.9%,
95% CI = 1.8–8.4, k= 1), UK and Europe (4.1%, 95% CI =
2.2–7.6, k= 2) and USA (5.7%, 95% CI = 2.5–12.6, k= 6).
Discussion
This is thought to be the ﬁrst meta-analysis to investigate
the prevalence of CR-PTSD in cancer survivors, and the
contribution of between-study heterogeneity to the ﬂuctu-
ation of these rates. Our data for all cancers indicated that
studies using clinical interview methods yield a mean
prevalence of 6.4% for current CR-PTSD and 12.6% for
lifetime CR-PTSD. Screening methods that used cluster
scoring indicated a prevalence of 13.8% for clinically
signiﬁcant CR-PTSD symptoms. The PCL-C yielded
lower event rates of clinically signiﬁcant CR-PTSD symp-
toms using the cut-off (7.3%) compared with symptom
cluster (11.2%), whereas the SCID yielded predictably
higher lifetime diagnoses (15.3%) than current diagnoses
(5.1%) for CR-PTSD.
These rates are similar to those found by Alter et al. [6]
in the DSM-IV Field Trials (4%), Green et al. [7] and
Palmer et al. [35], which identify a current CR-PTSD
prevalence of 2.5–5%. Epidemiological surveys reveal
the lifetime conditional risk (CR) of PTSD for women in
the US general population to be between 10.4% (95% CI =
8.8–11.7%) [43] and 13% (95% CI= 9.9–16.1%) [44].
Nevertheless, the lifetime CR-PTSD rate for our 100%
female US sample was 15.4% (95% CI = 8.4–26.7%),
which is higher than the CR for the USA, but within the
CIs for Breslau’s survey [44]. If 5–12% of cancer
survivors develop CR-PTSD, a trauma framework may
not represent the distress experienced by most patients—
as argued by Green et al. [7], Palmer et al. [35] and now
the DSM-5 task force [9]. This supports Kangas’s
criticism that the lack of differential diagnoses in semi-
structured clinical interviews challenges the validity of
PTSD diagnosis [10]. It does not, however, take into account
that the literature fails to record the presence/absence of
discrete catastrophic events within the course of the disease
that would make the cancer experience traumatic.
We recommend that clinicians consider the full range of
presentations, be aware of the nature of cancer as a
stressor and assess for discrete events that occurred during
the treatment to warrant a PTSD diagnosis and, in the
absence of these, consider a diagnosis of AD. If cancer
survivors meet AD criteria, this does not discount the
possibility of PTSD development. The literature shows
that cancer survivors present with subsyndromal symp-
toms [7,45,46], which are also associated with consider-
able functional impairments [26,45]. Although this too
may lead clinicians to initially question the validity of a
CR-PTSD diagnosis, it does not discount the possibility
that these subsyndromal symptoms may be a predictor of
future PTSD. DSM-5 course speciﬁers state that PTSD
may present with delayed expression, where only
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subsyndromal criteria are met before eventually meeting
full criteria at least 6 months post-trauma [9]. This is
supported by recent meta-analyses that show that delayed
expression is preceded by high stress sensitivity, addi-
tional life stressors, maladaptation to continued exposure
to stress and the steady accumulation of subsyndromal
symptoms from the onset of the stressor [47,48]. These
are features of cancer, and subsyndromal symptoms are
also present at the beginning of cancer treatment, ﬂuctuate
and persist throughout the course of the disease and may,
too, reﬂect a delayed PTSD presentation [15]. Although
rightly considered an adjustment response during treat-
ment, this may develop into CR-PTSD if those factors
prevent the cognitive processing of the illness.
In our moderator analysis, screening questionnaires
yielded higher rates of CR-PTSD symptoms than did the
use of clinical interviews for current CR-PTSD. The reasons
for this may be that whereas interviews diagnose disorder,
questionnaires detect clinically signiﬁcant symptoms, are
not clinician administered and do not screen for disorders
that better explain the symptoms [20]. However, the PCL-
C has demonstrated its reliable sensitivity and speciﬁcity
in correctly identifying clinical cases [11], but there is still
debate on where to place the cut-off score [20]. The
Davidson Trauma Scale [49] can be used as an alternative
to screen for CR-PTSD. It has a cut-off score that moves
depending on the prevalence of PTSD in the speciﬁc
population. As this meta-analysis revealed a current CR-
PTSD prevalence of 6.4%, the Davidson cut-off for the
cancer survivor population would be 47.
When lifetime CR-PTSD was assessed using the SCID,
prevalence decreased with time post-treatment. This ﬁnding
should be interpreted with caution. Firstly, this trend was
only observed for lifetime CR-PTSD, and secondly, this
factor is a proxy variable for time post-trauma. As there is
no agreement as to whether the diagnosis or the treatments
are the deﬁnitive traumas, investigators adopted one of the
two indices; therefore, these moderators could not be com-
bined, resulting in low statistical power. However, this ﬁnd-
ing reﬂects the epidemiologic trend that non-cancer PTSD
sufferers do recover naturally over time, although aminority
of them remain symptomatic after many years [43]. This has
implications for the survivors, as potential cases may not be
identiﬁed during routine follow-up, placing them at risk of
PTSD months to years after their treatment.
Younger-aged samples were associated with higher
current CR-PTSD event rates on the SCID. This trend
was just signiﬁcant, so these results too must be
interpreted cautiously. The majority of research into
this relationship concentrates on age at diagnosis—our
study-level moderator was the mean age of the sample.
Several of the samples were many months, or some-
times years, post-diagnosis, and this likely reduced
the sensitivity of our analysis—but as it addressed the
impact of younger age on the prevalence rates of
lifetime CR-PTSD (not on symptom severity)—it pro-
vides a singular contribution.
The ﬁnal aim was to synthesise disease-stage data to
establish whether they are a risk factor for PTSD following
comments that skewed samples characterised the research
[1]. Our post-hoc analyses suggested that advanced disease
is related to an increase in CR-PTSD event rates on PCL-C
and on the SCID. This is commensurate with studies that
show a positive relationship between disease severity and
CR-PTSD [8,27,33,34] and may provide some preliminary
support for this conclusion, but we advise cautious interpre-
tation. Although the differences in event rates were
signiﬁcant, additional factors may have contributed. The ad-
vanced disease sample in one study [41] was from a differ-
ent culture and set in palliative care, which introduces
environmental factors into the development of CR-PTSD
that are uncharacteristic of early-stage cancer samples. The
degrees of freedom for the early-stage group were larger
than those for the advanced-stage group and reﬂect the
abundance of earlier stage cancers in the majority of studies.
Publication bias
The funnel plots revealed substantial biases. However,
this is not the bias one would expect from the ﬁle-drawer
problem. Publication bias is identiﬁed by a skew in the
distribution towards higher effect sizes, at the bottom of
the funnel plot. The presence of this type of bias is not
visually depicted in our plots.
Strengths and limitations
There are limitations that constrain our conclusions. The
ﬁndings from the moderator analysis are tentative be-
cause several ﬁndings come from retaining k = 1 compar-
isons. This is problematic as the Q test has low power to
detect heterogeneity when k is low [50]. Nevertheless,
this highlights the need for concise, standardised and
transparent reporting to facilitate future meta-analytic
studies. Also, only study-level moderators were included.
Many studies did not assess psychiatric history or addi-
tional life stress at the time of assessment, so intraper-
sonal vulnerability factors were unaccounted for. The
substantial variability in reporting styles, and limitations
of using CMA, may have introduced variance into analy-
ses that is not attributable to the moderators of interest.
Studies that have used questionnaires may over-inﬂate
rates of CR-PTSD owing to symptom endorsement being
confounded by artefacts of cancer drugs, and medical
conditions [5], and realistic fears of cancer recurrence be-
ing endorsed as the acceptance of a foreshortened future.
Nevertheless, the sensitivity and speciﬁcity of the PCL-C
against the SCID for CR-PTSD are sufﬁcient to screen
for those survivors who may be suffering from an AD
or CR-PTSD. Out of the studies that have used inter-
views, few have assessed the rates of co-morbid
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disorders, meaning CR-PTSD might not be the primary
disorder. Also, all of the studies included in this meta-
analysis used DSM-IV criteria, not the new DSM-5.
Early epidemiological studies documented the inﬂation
of PTSD prevalence owing to the revised DSM-IV
criteria, so PTSD prevalence may decrease owing to the
new DSM-5 PTSD criterion A. The strengths of this inves-
tigation are that it included 25 studies and a substantial pa-
tient pool across several populations. This affords our
analysis generalisability that the individual studies could
not achieve [35]. Precision was enhanced by including data
for symptoms anchored to the experience of adult cancer.
This does not account for differential diagnoses but does
account for stress-related symptoms due to an extreme
stressor. In this case, the ﬁndings may reﬂect the proportion
of survivors who meet criteria for AD and PTSD. This is
more clinically useful than focusing on PTSD alone.
Future research
If the cancer experience is not generally traumatic, then the
fact that CR-PTSD does emerge in a signiﬁcant minority
of survivors suggests that other factors affect adjustment
and the cognitive processing of the illness. It has been argued
that ‘less traumatic’ stressors can be expected to trigger
PTSD in vulnerable individuals who have limited resources
to manage their response to stress [51] and that the insufﬁ-
ciency of some events to meet PTSD criterion A may reﬂect
failure to consider the role of personal stress reactivity
[52,53], and the effect of allostatic load [53]. As such, there
is less information on variables that inﬂuence this adjust-
ment. Variables such as social support and/or constraints
on talking about the illness [21,28,30,54–58], emotion regu-
lation strategies such as dissociation [22], emotional suppres-
sion and avoidance [59,60], and rumination [61] have been
identiﬁed as predictors of PTSD symptoms in cancer
populations.Most recently, emotional processing styles have
been implicated in post-natal depression [62] and PTSD
[63,64]. Given the protracted nature of cancer, it is possible
that social variables and their relationship to beliefs about
experiencing and expressing of emotions may inﬂuence cog-
nitive processing over the course of disease and predict the
emergence of CR-PTSD. This necessitates further
investigation on the role of these variables in multiple oncol-
ogy services both nationally and internationally. But ﬁrstly,
in order to assess the risk of CR-PTSD in this population,
it may be necessary to report, or make readily available,
the raw data on CR-PTSD event rates by (a) disease stage,
(b) cancer type, (c) treatment regimens, (d) any traumatic
events during the course of the disease, (e) age at diagnosis
and (f) the mean time of assessment in relation to time
post-diagnosis and time post-treatment.
Conclusions
Prevalence rates from questionnaires reveal that a minority
of cancer survivors present with clinically signiﬁcant symp-
toms due to cancer. In these cases, we recommend that on-
cology specialists recognise the possibility of CR-PTSD
and refer their patient to mental health services. Prevalence
rates from clinical interviews show that a minority of cancer
survivors meet (or have previously met) full DSM-IV
criteria for CR-PTSD after the conclusion of treatment and
that those who are younger, diagnosed with more advanced
disease or recently completed treatment may be at greater
risk of CR-PTSD. Methodological heterogeneity prohibits
robust conclusions about the expected prevalence of CR-
PTSD as a primary disorder but does provide some clinical
justiﬁcation for the diagnosis of a CR-PTSD in a minority of
cases. Given the release of the DSM-5, we recommend
caution in diagnosing CR-PTSD but advise further investi-
gation into whether traumatic occurrences were experienced
during the course of the disease.
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